Term
| What are the 3 types of mAbs? |
|
Definition
- Chimeric/ximab
- Humanized/zumab
- Human/mumab |
|
|
Term
| What mAb drugs target CD20? |
|
Definition
- Rituximab - IV
- Ofatumumab - IV
**CD20 on 90% of B-cell lymphomas -- apoptosis via ADCC/CDC |
|
|
Term
| What mAb drugs target CD52 or CD30? |
|
Definition
- Alemtuzumab - CD52, an antigen on lymptocytes/lymphoma. IV, SEVERE myelosuppression
- Brenttuximab - internalization of CD30, microtubule disrupting MMAE. PN, infusion rxn |
|
|
Term
| What mAb drugs are anti-EGFR? |
|
Definition
- Cetuximab - IV. Cardiopulmonary arrest
- Panitumumab - no ADCC, blocks EGF-R. IV - rash, diarrhea
Block the EGF-receptor, not blocking phosphorylation, apoptosis via ADCC |
|
|
Term
| What mAb drugs are anti-HER2? |
|
Definition
- Trastuzumab - ADCC.
- Trastuzumab emtansine - + microtubule inhibitor. Cardio + PN
- Pertuzumab - inhibits dimerization, ADCC. Teratogen
**HER2 overexpression in 30% breast cancer - resistance to cytotoxic and anti-hormonal therapy
**All cardiotoxic |
|
|
Term
| What mAb drugs are anti-VEGF? |
|
Definition
- Bevacizumab - HEMORRHAGE, poor wound healing
- Ziv-aflibercept - decoy for VEGF, not a true antibody. Hemorrhage + poor wound healing.
**Sequestration of VEGF - the growth factor. Does NOT affect receptor. |
|
|
Term
| What are common features of mAb? |
|
Definition
- dose-dependent PK
- Infusion rxns
- IV dosing
**HER2 = cardiotoxicity |
|
|
